Benzodiazepine treatment of substance abusers with anxiety disorders is usually discouraged, be cause of the abuse potential of these medications, as well as specific complications of these medica tions such as violent dyscontrol syndromes (Ameri can Psychiatric Association, 1990; Barlow, 1997; Cole and Kando, 1993; Michelini et al., 1996; Mueller et al., 1996; Rickels and Downing, 1974; Risse et al., 1990; Rosenbaum et al., 1984; Salzman, 1997) . Al though substance abuse is one of the most common comorbid disorders in posttraumatic stress disorder (PTSD), these medications have been frequently used in treating PTSD (Chilcoat and Breslau, 1998; Cottler et al., 1992; Kessler et al., 1995; Kulka et al., 1990 Kulka et al., , 1998 Laufer et al., 1981; Najavits et al., 1998; Orsillo et al., 1996) . The relative prohibition in using benzodiazepines among substance abusers (except for acute detoxification) has been well disseminated clinically, with the Veterans Administration Health care System (VA) specifically alerting clinicians to this potential problem in treating PTSD during the early 1990s (Ashton, 1994; Fontana and Rosenheck, 1996; Uhlenhuth et al., 1995) . Thus, a large 1-year follow-up study of PTSD outpatient care that was conducted in the 2 years after this VA alert offered an opportunity to examine this issue from several perspectives (Fontana and Rosenheck, 1997) . These perspectives include whether such an administra tive alert would sufficiently impact clinical practice to virtually eliminate all benzodiazepine prescribing to substance abusers with PTSD, or whether sub stance abusers might be more carefully selected by clinicians following this alert to minimize complica tions in these patients.
An initial question in this study of veterans who were followed after short-term hospitalization for PTSD was whether benzodiazepine pharmacother apy after discharge was less frequently prescribed for substance abusers with PTSD. For comparison, we also examined antidepressants, which have been the most common pharmacotherapy for PTSD to de termine whether substance abusers were simply less likely to get pharmacotherapy for their PTSD (Frank et al., 1988; Friedman, 1988) . Although many characteristics of the outpatient care besides the pharmacotherapy might contribute to differences in outcome, a second question was whether those sub stance abusers given benzodiazepines had a worse outcome than either the non-substance abusers or than the substance abusers that were not given ben zodiazepines. The specific outcomes that might be worse for the substance abusers who were given these medications include alcohol and drug abuse itself, particularly sedative abuse and violence, be cause recent work has indicated that substance abusers are at higher risk of violence associated with benzodiazepine use (Rickels and Downing, 1974; Risse et al., 1990; Salzman, 1997) .
A third question was whether benzodiazepines would increase the need and costs for outpatient or inpatient care among those substance abusers given benzodiazepines. Substance abusers might have greater health service utilization not only for detox ification but also due to disinhibition of violence by benzodiazepines (Bremmer et al., 1996; Cole and Kando, 1993; Michelini et al., 1996) . Moreover, be cause benzodiazepines relieve anxiety, this relief could reduce the number of emergency room visits and hospitalizations due to crises associated with the PTSD and amplify the difference between the abusers and nonabusers given benzodiazepines. Thus, we also compared substance abusers to nonabusers on outpatient and subsequent inpatient care utilization during the 1-year follow-up.
Methods
This study was a quasi-experimental design com paring specialized to nonspecialized short-term in patient care for PTSD at nine different sites within the VA, as described elsewhere (Fontana and Rosenheck, 1997) . Five units were a general psychi atry type (GEN), the other four were specialized 1 month inpatient programs for PTSD (EBPTU). These inpatient programs represented substantial geographic diversity across the United States as de scribed elsewhere and were chosen to represent the diversity of veterans with PTSD treated within the Department of Veterans Affairs (Fontana and Rosenheck, 1997) . In the original study, a third treat ment setting-long-term inpatient care-was also examined, but the veterans in that program were unlikely to get any medications at follow-up. For ex ample, less than 4% of those leaving the long-term inpatient care were prescribed benzodiazepiries mak ing any comparison between users and nonusers un informative due to the small number of subjects.
Within these two short-term programs 541 veter ans were examined at baseline, but during a 1-year follow-up, only 370 (68%) were available. All had a diagnosis of PTSD, and about half had substance use disorders that were diagnosed using a clinical interview with DSM-III criteria. All were men and the average age was 45 years old. Most veterans were white (75%). Only 6% were never married, but over half of those married had been divorced. Al though only 5% were employed full-time, this low rate reflects their status upon entry into the inpa tient treatment program, not their employment sta tus during the one-year follow-up. However, about half were service-connected for PTSD and 20% were service-connected for some other disorder and not considered currently employable. The EBPTU pro gram treated about half of the veterans, and most had had previous inpatient care (85%). Medication was used in over 80%, as ascertained by self-report, which specified medication type, but not medication dosage or brand name. Participation in these as sessments followed written informed consent.
At baseline and during the 1-year follow-up at 4, 8, and 12 months after discharge, outcome measures included inpatient and outpatient health services utilization, severity of alcohol and illicit drug use, anxiety and PTSD symptoms, psychosocial func tioning, and violence. Substance abuse and psy chosocial outcome were assessed using the Addic tion Severity Index (ASI; McLellan et al., 1985) . Anxiety was assessed using the Brief Symptom In ventory (BSI), violent actions were assessed using a self-report instrument derived from the National Vietnam Veterans Readjustment Study (NVVRS), and PTSD specific symptoms were assessed using the Mississippi Scale for PTSD (Derogatis and Melisaratos, 1983; Keane et al., 1988; Kulka et al., 1990) .
Baseline comparisons between benzodiazepine treated and untreated veterans were conducted using chi-squared and simple t-tests. The character istics showing a difference were then entered into a stepwise discriminant function to select those char acteristics that independently contributed at least 2% to the overall variance of being treated with ben zodiazepines. These characteristics then were used as covariates for further analyses of outcome. The outcome measures such as violence, the ASi and the other psychological scales were analyzed using a random regression model (RRM) from SAS 6.12 (PROC Mixed). Our model was based on an autore gressive order one covariance structure, with linear time interactions (Gibbons et al., 1993; Jenrich and Schluchter, 1986) . With this RRM approach, we had 370 of 541 potential subjects (68% follow-up) for the comparisons of the aftercare following the two short-term inpatient programs (EBPTU and GEN).
The first set of analyses examined the impact of benzodiazepines on time trends for each of the out comes. In addition to the covariates mentioned pre viously, each model included terms representing main effects of time and benzodiazepine use and the interaction of benzodiazepine use and time. A sig nificant time by benzodiazepine interaction was taken as evidence of an effect of benzodiazepine use on outcomes. A second set of analyses then exam ined whether time trends with benzodiazepines dif fered among patients with current substance abuse and those without such problems. These analyses included terms representing main effects for benzo diazepine use, time and substance abuse; two-way interaction terms between each of the three pairs of these factors; and a three-way interaction of time, benzodiazepine use, and substance abuse. The three-way interaction term was used to identify any difference in benzodiazepine effect associated with substance abuse.
Results
Pharmacotherapy was used commonly with both substance abusers and nonabusers during the out patient care of these veterans. The most common medications used were antidepressants and benzo diazepines with 90% of the treated patients given ei ther one or both of these medications. Other med ications such as antipsychotic agents and lithium were infrequently used. One or both of these med ications were used by 72% of the EBPTU and 85% of the GEN veterans, but benzodiazepines were used less often by the EBPTU than by the GEN veterans (25% vs. 47%) (x 2 = 14; p < .001). Antidepressants were prescribed to 71% of the substance abusers and 66% of the nonabusers. In comparison, only 26% of the substance abusers and 45% of the nonabusers were given benzodiazepines (x 2 = 14; p < .001). Prescription of benzodiazepines showed no inter action between program type and substance abuse. The rates of prescription for substance abusers were about half the rate of the non-substance abusers in both types of programs (18% vs. 31% for EBPTU and 34% vs. 59% for GEN; for the interac tion: F = 1.5; df = 1,369; p < .3). Among the sub stance abusers, 63 (17% of all subjects) had a history of sedative abuse, but the rates of benzodiazepine prescribing did not differ between these abusers and nonabusers (36% vs. 38%).
As shown in Table 1 , independent of substance abuse, benzodiazepine-treated veterans were more likely to have been previously hospitalized, had more severe PTSD symptoms, and had more anxiety and overall psychiatric symptoms on the BSI. They were more likely to be also prescribed antidepres sants and less likely to have an alcohol or drug abuse diagnosis. Independent of benzodiazepine use, the substance abusers had higher Helzer scores, more severe drug abuse severity, and more family instability. For age, alcohol problems and re ceipt of VA disability benefits, the veterans differed on both benzodiazepine use and substance abuse. All of these distinguishing characteristics were en tered into a stepwise discriminant function and four were selected as making at least a 2% contribution to the variance in being prescribed benzodiazepines: age, ASI alcohol problems, PTSD symptoms, and service connection. When separated into substance abusers and nonabusers, two discriminating charac teristics for benzodiazepine prescription were the same for abusers or nonabusers: age and receipt of VA disability benefits. Two other characteristics dis tinguished benzodiazepine prescribing for only sub stance abusers or nonabusers, but not both: BSI anxiety discriminated only among the substance abusers and PTSD severity discriminated only among the nonabusers. Finally, a more complex four-group discrimination yielded similar discrimi nators: age, service connection, anxiety, and prior hospitalization. Table 2 provides the mean change from baseline to 1 year follow-up for 10 outcomes as well as out patient and inpatient service utilization (days/year). As shown, benzodiazepine use had no significant im pact on clinical outcome in either substance abusers or nonabusers, but substance abusers had significant reductions in both alcohol problems and violence. Although violence did not differ at base line, as shown in Table 1 , it was significantly higher in the benzodiazepine treated veterans at the 4-, 8-, and 12-month follow-up using simple t-tests (data not shown). By using a random regression model to examine changes over time, however, violence showed no significant time interactions with benzo diazepine use. Thus, benzodiazepine use did not make either violence or substance abuse worse for the substance abusers, although substance abusing veterans treated with benzodiazepines showed less improvement on both outcomes than those not given benzodiazepines.
For healthcare utilization the veterans treated with benzodiazepines had fewer outpatient visits per year (OPV; 64 vs. 32 visits, t = 3.4; df = 364; p < .001) but no significant difference in inpatient days (22 vs. 29 days) . Furthermore, among the substance abusers inpatient days were the same whether or not treated with benzodiazepines (29 days). The out patient difference was greatest for the first 4 months (27 vs. 17 visits, t = 3.7; p < .001) and was not sig nificant for the last 4-month block between months 8 and 12 (19 vs. 16 visits) . Covariance adjustments for program type, baseline differences, and alcohol abuse had little effect on this difference in OPV.
Discussion
The veterans treated with benzodiazepines after a brief hospitalization for PTSD had more severe PTSD symptoms and less severe alcohol problems as well as being slightly younger. The substance abusers treated with benzodiazepines did not have worse outcomes. A surprising finding was the re duction in outpatient healthcare utilization with benzodiazepine treatment of the substance abusers. This difference in 32 compared with 64 visits per a= Not significant. Significance levels reflect two-and three-way interactions of benzodiazepines with time (benzodiazepine), sub stance abuse with time (SA), benzodiazepines, and substance abuse with time (X time); (three-way interaction).
b= Addiction Severity Index and Brief Symptom Inventory change scores for composite scales have been multiplied by 100 for pre sentation; negative scores indicate worsening during follow-up.
c= Outpatient and inpatient days reflect average total days for whole year.
year represents savings of $600 to $1200 per patient, per year, in outpatient care. Although it might be ar gued that more outpatient care is superior, the aver age number of outpatient treatments was substan tial for the benzodiazepine treated patients with over 30 visits/year. The contribution of benzodiazepines to this lower utilization cannot be sepa rated from differences in practice patterns among the practitioners included in this follow-up, how ever. Only future placebo controlled studies using randomization and perhaps stratification of pro viders by those who focus more on psychotherapies versus those who rely more on medications and per haps less frequent outpatient visits. Previous alcohol abuse has been considered a risk factor for developing increased violence as well as worsening suhstance abuse while taking benzodi azepines, but benzodiazepine-treated veterans with alcohol abuse showed no differences from untreated veterans during the follow-up (American Psychiatric Association, 1990; Barlow, 1997; Michelini et al., 1996; Nunes et al., 1995; Rickels and Downing, 1974; Salzman, 1997) . Because no previous large scale study has examined this clinical assertion of alco holism as a risk factor for violence, this assertion may be incorrect. Alternatively, the treating clini cians appeared to be aware of this potential risk fac tor, because the severity of alcohol problems was significantly lower in the benzodiazepine treated compared with untreated veterans at hospital entry. These findings suggest that clinicians may have been able to select their substance abuse patients for benzodiazepine use in order to minimize the po tential for violence. However, these selection fac tors for benzodiazepine use in substance abusers were not obvious in this study, and their identifica tion remains a goal for future studies.
Besides alcohol problem severity, the other two clinical factors uniquely contributing to a decision for benzodiazepine treatment were severity of PTSD as assessed by the Mississippi Scale and receipt of VA disability benefits for PTSD. These two measures reflect not only the severity of PTSD symptoms, but also the disability associated with PTSD in these veterans. Interestingly, however, benzodiazepine treatment did not improve either the anxiety symp toms of these veterans nor their social functioning in employment, legal or family areas. Thus, the ther apeutic role of chronic benzodiazepines in PTSD is not clear.
This study has several limitations in its nonran dom allocation to medications and reliance on self reports rather than toxicology verified substance abuse outcomes. Because of nonrandom allocation, we checked for demographic or clinical differences between the medication groups at baseline. We ad justed for these differences, and we added covari ates for baseline PTSD and general symptom levels without effecting the main findings. Self-report limi tations may have biased the reporting of adverse events by the veterans given benzodiazepines, but serious complications leading to hospitalization in cluding the need for detoxification were not evident. Self-reports in this PTSD population have also shown excellent validity compared with urine toxi cology . Other limitations are the pooling of various medications into two broad classes and the lack of dosing information or com pliance measures. Although these can be serious limitations due to potential under-dosing for many medications, benzodiazepines tend to be requested by patients and compliance is good. If these med ications were under-dosed, this would bias against their potential efficacy and suggests that our effect sizes may be minimal estimates of the efficacy for their addition to PTSD treatment. In conclusion, benzodiazepines may put some veterans with PTSD at risk for violence, but neither alcoholism nor rela tively lower levels of outpatient care appear to identify a high-risk group for violence or other psychosocial complications or poor treatment out comes.
